Weekly pill trial aims to ease agonizing bone pain for sickle cell patients
NCT ID NCT06016634
First seen Jan 05, 2026 · Last updated Apr 11, 2026 · Updated 10 times
Summary
This study is testing if a weekly pill called alendronate is safe and can help adults with sickle cell disease who have a painful bone condition called osteonecrosis. Researchers will give the pill to about 30 participants for 6 months to see if it reduces pain and improves bone health. The main goals are to check if people can stick with the treatment and to measure changes in their pain levels and bone markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.